[go: up one dir, main page]

AR104185A1 - Formulaciones farmacéuticas - Google Patents

Formulaciones farmacéuticas

Info

Publication number
AR104185A1
AR104185A1 ARP160100918A ARP160100918A AR104185A1 AR 104185 A1 AR104185 A1 AR 104185A1 AR P160100918 A ARP160100918 A AR P160100918A AR P160100918 A ARP160100918 A AR P160100918A AR 104185 A1 AR104185 A1 AR 104185A1
Authority
AR
Argentina
Prior art keywords
formulations
pharmaceutical formulations
oxo
crystals
ethyl
Prior art date
Application number
ARP160100918A
Other languages
English (en)
Inventor
Chandra Gupta Ramesh
Kesarwani Amit
Mishra Vivek
Abraham Jaya
Dutt Chaitanya
Chaudhari Anita
Patel Manish
Latad Sachin
Kotecha Jignesh
Mathur Anoop
Kumar Zambad Shital
Deshpande Shailesh
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of AR104185A1 publication Critical patent/AR104185A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulaciones farmacéuticas que comprenden 1-(2-tien-2-il-2-oxo-etil)-3-(metanosulfonil hidracina carbonil)piridinio, sus sales farmacéuticamente aceptables, sal-cocristales y co-cristales, particularmente 1-(2-tien-2-il-2-oxo-etil)-3-(metanosulfonil hidracina carbonil)cloruro de piridinio. Las formulaciones son adecuadas para la administración por vía oral y también comprenden un potenciador de permeabilidad o una base adecuada o una mezcla de los mismos. Las formulaciones para tratar enfermedades asociadas con productos finales de glicación avanzada. Uso.
ARP160100918A 2015-04-08 2016-04-05 Formulaciones farmacéuticas AR104185A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1475MU2015 2015-04-08

Publications (1)

Publication Number Publication Date
AR104185A1 true AR104185A1 (es) 2017-07-05

Family

ID=55808800

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100918A AR104185A1 (es) 2015-04-08 2016-04-05 Formulaciones farmacéuticas

Country Status (31)

Country Link
US (1) US10772879B2 (es)
EP (1) EP3280447B1 (es)
JP (1) JP6736656B2 (es)
KR (1) KR20170134662A (es)
CN (1) CN107530287B (es)
AR (1) AR104185A1 (es)
AU (1) AU2016246124B2 (es)
BR (1) BR112017021669A2 (es)
CA (1) CA2997463A1 (es)
CY (1) CY1121921T1 (es)
DK (1) DK3280447T3 (es)
EA (1) EA037041B1 (es)
ES (1) ES2724629T3 (es)
HR (1) HRP20190783T1 (es)
HU (1) HUE044889T2 (es)
IL (1) IL254794B (es)
LT (1) LT3280447T (es)
MX (1) MX387639B (es)
MY (1) MY182008A (es)
PH (1) PH12017501829A1 (es)
PL (1) PL3280447T3 (es)
PT (1) PT3280447T (es)
RS (1) RS58708B1 (es)
SG (1) SG11201708142XA (es)
SI (1) SI3280447T1 (es)
SM (1) SMT201900264T1 (es)
TR (1) TR201906476T4 (es)
TW (1) TWI713512B (es)
UA (1) UA123051C2 (es)
WO (1) WO2016162787A1 (es)
ZA (1) ZA201707094B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876883C (en) 2012-06-15 2022-11-01 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
DK2976072T3 (da) 2013-03-22 2021-08-16 Univ Nova Southeastern Epinephrinfinpartikler og fremgangsmåder til anvendelse deraf til behandling af tilstande, der reagerer på epinephrin
AU2019361136B2 (en) 2018-10-19 2025-08-14 Nova Southeastern University Sublingual epinephrine compositions including pH-modifying excipients and penetration enhancers and methods for use thereof
MY204603A (en) 2019-04-03 2024-09-05 Astellas Pharma Inc Pharmaceutical composition
KR102330597B1 (ko) * 2020-04-17 2021-11-26 보령제약 주식회사 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형
KR20220080880A (ko) * 2020-12-08 2022-06-15 주식회사 종근당 엠파글리플로진 공결정을 함유하는 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2681300A (en) * 1999-02-22 2000-09-14 Elan Corporation, Plc Solid oral dosage form containing an enhancer
CZ291789B6 (cs) * 1999-10-06 2003-05-14 Torrent Pharmaceuticals Ltd Pyridiniová sloučenina, způsob její výroby, její použití, farmaceutický prostředek ji obsahující a jeho použití
ES2243389T3 (es) 2001-03-21 2005-12-01 Torrent Pharmaceuticals Ltd Compuestos de piridinio utiles para el tratamiento de enfermedades relacionadas con los age.
CA2644578A1 (en) 2006-03-03 2007-09-07 Torrent Pharmaceuticals Ltd Novel dual action receptors antagonists (dara) at the ati and eta receptors
JP2009023932A (ja) * 2007-07-18 2009-02-05 Tama Tlo Kk Ｎ−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料
BRPI0907650A2 (pt) * 2008-01-25 2015-07-21 Torrent Pharmaceuticals Ltd Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc
CN101574343B (zh) * 2008-05-07 2011-06-01 吉林大学 一种治疗糖尿病的药物组合物
TW201102380A (en) * 2009-05-07 2011-01-16 Torrent Pharmaceuticals Ltd Novel heterocyclic compounds
WO2011084618A2 (en) * 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN104069066B (zh) * 2013-03-25 2017-04-19 吉林大学 黄癸固体分散体及其在治疗糖尿病及并发症中的应用

Also Published As

Publication number Publication date
EA201792237A1 (ru) 2018-02-28
CN107530287A (zh) 2018-01-02
SMT201900264T1 (it) 2019-07-11
IL254794A0 (en) 2017-12-31
WO2016162787A1 (en) 2016-10-13
DK3280447T3 (da) 2019-05-13
TR201906476T4 (tr) 2019-05-21
JP6736656B2 (ja) 2020-08-05
EP3280447A1 (en) 2018-02-14
CN107530287B (zh) 2020-11-10
TWI713512B (zh) 2020-12-21
AU2016246124B2 (en) 2019-11-14
EA037041B1 (ru) 2021-01-29
LT3280447T (lt) 2019-05-27
ES2724629T3 (es) 2019-09-12
PT3280447T (pt) 2019-05-14
SI3280447T1 (sl) 2019-06-28
UA123051C2 (uk) 2021-02-10
HRP20190783T1 (hr) 2019-06-28
ZA201707094B (en) 2021-04-28
JP2018510916A (ja) 2018-04-19
CA2997463A1 (en) 2016-10-13
SG11201708142XA (en) 2017-11-29
BR112017021669A2 (pt) 2018-07-10
PL3280447T3 (pl) 2019-07-31
RS58708B1 (sr) 2019-06-28
US10772879B2 (en) 2020-09-15
PH12017501829A1 (en) 2018-04-23
AU2016246124A1 (en) 2017-11-02
IL254794B (en) 2021-05-31
US20180110763A1 (en) 2018-04-26
HUE044889T2 (hu) 2019-11-28
MX387639B (es) 2025-03-18
KR20170134662A (ko) 2017-12-06
MX2017012942A (es) 2018-01-30
MY182008A (en) 2021-01-18
EP3280447B1 (en) 2019-02-27
TW201642858A (zh) 2016-12-16
CY1121921T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
AR104185A1 (es) Formulaciones farmacéuticas
DOP2017000306A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
UA122346C2 (uk) ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CR20160527A (es) Derivados de carboxamida
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
CL2018001151A1 (es) Suspensión acuosa para administración oral y método para su preparación
AR105758A1 (es) Formulación farmacéutica compleja que comprende amlodipina, losartan y clortalidona
SI3746441T1 (sl) Farmacevtska spojina, njene soli, njene formulacije ter postopki izdelave in uporabe le-teh
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MX2015009364A (es) Uso de sales de tungsteno (vi) para el tratamiento de infertilidad femenina en mamiferos no diabeticos.
EP3873437A4 (en) AQUEOUS PHARMACEUTICAL FORMULATIONS
MX373227B (es) Sales farmacéuticamente aceptables de enantiómeros de pirlindol para utilizarse en medicina.
AR103484A1 (es) Triptólido y sus derivados en el tratamiento de tumores y patologías precancerosas de la piel
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας

Legal Events

Date Code Title Description
FB Suspension of granting procedure